The Quantellect read.As of Nov 19, 2026, 5 active firms cover Elicio Therapeutics Inc: 4 rate it Buy or better, 1 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets range widely, $8.00 to $23.00 (about 2.9x), a sign of real disagreement on valuation. The average target of $15.00 sits 843% above the current $1.59. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.33 next quarter toward $-1.34 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS5 active firms
Buy
Strong Buy00%
Buy480%
Neutral120%
Sell00%
Strong Sell00%
Based on 5 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$15.00
+843.4% upside
Average target across 4 active firms as of Nov 19, 2026 vs $1.59 current
Highest Target$23.00
Average Target$15.00
Lowest Target$8.00
Detailed analyst forecasts for ELTX
Showing 1–6 of 6 named analysts shown · 5 active firms in the rating projection
As of Nov 19, 2026, 4 of 5 active firms rate ELTX a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
ELTX EPS & revenue forecast
EPS · NEXT QUARTER
$-0.33
Range $-0.51 – $-0.20 · 3 analysts · -49% YoY
Next period, 3 analysts expect Elicio Therapeutics Inc. to earn $-0.33 a share (range $-0.51 – $-0.20), versus $-0.65 a year earlier. Full-year consensus is $-1.63, growing to $-1.34 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 3 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Elicio Therapeutics Inc.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ELTX.
#1
Mayank Mamtani
B. Riley Securities · Rank #36
Buy
$8.00+403.1% to target
Overall win rate
49%
+ Follow
#2
RB
Robert Burns
HC Wainwright & Co. · Rank #215
Buy
$23.00+1346.5% to target
Overall win rate
42%
+ Follow
#3
Aydin Huseynov
Ladenburg Thalmann · Rank #564
Buy
$20.00+1157.9% to target
Overall win rate
32%
+ Follow
#4
MK
Michael King
Rodman & Renshaw
Buy
$17.00+969.2% to target
Coverage
—
+ Follow
#5
KD
Kevin DeGeeter
Ladenburg Thalmann
Buy
$12.00+654.7% to target
Coverage
—
+ Follow
ELTX stock forecast FAQ
What is ELTX's average 12-month price target?+
The 4 active firms with a live target average $15.00 for Elicio Therapeutics Inc. over the next 12 months, ranging from a $23.00 high to a $8.00 low, as of Nov 19, 2026.
Is ELTX stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 5 active firms as of Nov 19, 2026, 4 rate it Buy or Strong Buy, 1 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for ELTX?+
The Street-high target is $23.00 (HC Wainwright & Co.), and the Street-low is $8.00 (B. Riley Securities). The average of all 4 active-firm targets is $15.00.
How many active Wall Street firms cover ELTX?+
5 active firms have a recognized rating on Elicio Therapeutics Inc. as of Nov 19, 2026, and 4 active firms carry a live 12-month price target.
Who is the most accurate analyst covering ELTX?+
Among analysts who currently cover ELTX, Mayank Mamtani of B. Riley Securities has the strongest overall Quantellect track record (Rank #36). Their current call is Buy with a $8.00 target.
What is Elicio Therapeutics Inc.'s projected EPS for next quarter?+
The consensus estimate is $-0.33 per share (range $-0.51 – $-0.20) across 3 analysts. Full-year EPS is projected at $-1.63, rising to $-1.34 the following year.
How much revenue is Elicio Therapeutics Inc. expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading ELTX lately?+
As of Nov 19, 2026, 4 of 5 active firms rate ELTX a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ELTX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.